SEPN: Septerna, Inc. Kompaniya qiymatining sof foydaga nisbati
Septerna Inc joriy sotuvlarga ega emas, chunki uning muvaffaqiyati ilmiy grantlarga bog'liq. Rahbariyat metabolik patologiyalarga qarshi kurashish uchun GPCR retseptorlariga e'tibor qaratmoqda. Biroq, patentlar orqali kengayish salohiyati ulkan marjalarni va'da qilmoqda, bu esa GURU.Markets platformasidagi kompaniyaning bazaviy P/E ko'rsatkichi bilan tasdiqlanadi, u yerda -96.80 indikatorning joriy qiymati bo'lib, aktiv uchun o'z vaqtida ortiqcha to'lov qilishning oldini olishga yordam beradi.
%20P%2FE%20multiplikatori&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_SEPN_-_Septerna-Inc_-_PE-Multiple "SEPN: Septerna Inc Biznesning o‘zini qoplash muddati 17.05.2025 - 10.11.2026 | 👁️GURU.Markets👁️")
Septerna Corp (SEPN) kompaniyasining tahliliy kesimlari
- narx va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi haqida ma'lumot:
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Umumiy qarzning xususiy kapitalga nisbati Septerna Inc|SEPN - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati Septerna Pharma|SEPN - Kompaniya qarzlari|Qarzning balans qiymatiga nisbati Septerna Inc|SEPN - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz Septerna|Oraliq qoplama koeffitsiyenti septerna.com
- foyda va bozor multiplikatorlari tafsilotlari:
SEPN - Sof foyda|Kutilayotgan sof foyda Septerna Inc|SEPN - Narxning foydaga nisbati|Narxning kutilayotgan foydaga nisbati Septerna, Inc.|SEPN - Narx-foyda va o‘sish multiplikatori|Korxona qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati koeffitsiyenti Septerna Inc|SEPN - EBITDA operatsion foydasi|So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda Septerna|SEPN - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi 12 oy davomida bitta aksiya uchun foydaning yillik o'sishi septerna.com|SEPN - Joriy yilda bir aksiya uchun foyda o'sishi|Keyingi yil uchun bir aksiya uchun foydaning prognoz qilingan o'sish sur'ati Septerna Inc
Kompaniyaning har tomonlama tahlili:septerna.com SEPN
Innovatsion Native Complex platformasi Septerna Inc (SEPN) kompaniyasiga ilgari yetib bo'lmaydigan GPCR retseptorlari uchun oral dori vositalarini ishlab chiqish imkonini beradi va endokrinologiya sohasida texnologik yutuqni taqdim etadi. Kompaniyaning P/E baholash profili bir dollar sof foydaning bozor qiymatini aks ettiradi, bu esa aktivning premiumini aniqlash hamda aksiyaning davlat subsidiyalari va soliq rejimidagi o'zgarishlarga nisbatan barqarorligini baholash imkonini beradi.
Muhim raqobatchilar
P/E multiplikatori argenx.com|Narx-foyda koeffitsiyenti BNTX (BioNTech)|ABVX (ABIVAX) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ADMA (ADMA Bio)|Biznesning o‘zini qoplash muddati Protagonist Corp (PTGX)|IMVT - Narxning foydaga nisbati|kiniksa.com (KNSA) - Narx-foyda koeffitsiyenti|Grifols (GRFS) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti Adaptive Biotech|Narx-foyda koeffitsiyenti CLDX|P/E multiplikatori Aurinia Corp|Narxning foydaga nisbati BioCryst (BCRX)|veratx.com - Narx-foyda multiplikatori|P/E multiplikatori DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Kapitalizatsiyaning foydaga nisbati|ABCL - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Tourmaline TRML|PGEN: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati pharming.com (PHAR)|Narxning foydaga nisbati Nektar Therapeutics Inc.|Upstream Bio, Inc. - Kapitalizatsiyaning sof foydaga nisbati|Narx-foyda koeffitsiyenti ZBIO (Zenas Biopharma, Inc.)|Bozor narxining sof foydaga nisbati IMNM|P/E multiplikatori GOSS (Gossamer Bio, Inc.)|kalvista.com (KALV) - Kapitalizatsiyaning foydaga nisbati|PVLA - Narxning foydaga nisbati|Kompaniya qiymatining sof foydaga nisbati SVRA (Savara Inc)|Rigel Pharmaceuticals Inc (RIGL) - Narxning foydaga nisbati|Narx-foyda multiplikatori ANAB|ATXS (Astria Therapeutics) - P/E multiplikatori|P/E multiplikatori engene.com|Narx-foyda koeffitsiyenti RAPT (RAPT Therapeutics)|JBIO (aerovatetx.com) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ACRS (Aclaris)|Biznesning o‘zini qoplash muddati Kyverna Therapeutics, Inc (KYTX)|TLSA - Narxning foydaga nisbati|CABA (cabalettabio.com) - Narx-foyda multiplikatori|VTYX: P/E multiplikatori|Narx-foyda koeffitsiyenti Theratechnologies, Inc.|Narxning foydaga nisbati Avalo Therapeutics Inc.|Eledon Pharmaceuticals, Inc (ELDN) - Biznesning o‘zini qoplash muddati|P/E multiplikatori AGEN|CLYM - Kapitalizatsiyaning foydaga nisbati|Narxning foydaga nisbati Zura Bio ZURA|ATYR (aTyr Pharma Inc) - Kapitalizatsiyaning sof foydaga nisbati|ADAG - Narxning foydaga nisbati|IMA (ImageneBio Inc) - Narx-foyda multiplikatori|shattucklabs.com (STTK) - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati EQ (Equillium)|CNTB (Connect Biopharma Holdings) - P/E multiplikatori|IMUX: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ATRA|P/E multiplikatori inflarx.de (IFRX)|Narxning foydaga nisbati X4 Pharmaceuticals XFOR|Kompaniya qiymatining sof foydaga nisbati ACET|CELU - Narxning foydaga nisbati|INmune Bio Inc (INMB) - Narx-foyda koeffitsiyenti|BRNS: P/E multiplikatori|Kezar Life Sciences Inc (KZR) - P/E multiplikatori|Narx-foyda koeffitsiyenti SABS|AKTX: Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori ENLV|Biznesning o‘zini qoplash muddati q32bio.com|Narxning foydaga nisbati GeoVax Labs Inc GOVX|EDSA - Narx-foyda koeffitsiyenti|IBIO - Narxning foydaga nisbati|Carisma Therapeutics (CARM) - Narx-foyda koeffitsiyenti|XTLB (XTL Biopharmaceuticals Ltd.) - Narx-foyda koeffitsiyenti|Bolt Biotherapeutics, Inc. (BOLT) - P/E multiplikatori|Narxning foydaga nisbati HCW Biologics, Inc.|Narx-foyda multiplikatori APVO (Aptevo)|P/E multiplikatori AIM|ADTX - Kapitalizatsiyaning foydaga nisbati|Narxning foydaga nisbati GRI Bio GRI|Biznesning o‘zini qoplash muddati XORTX Therapeutics Inc (XRTX)|ReShape Lifesciences - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Revelation Biosciences Corp|Indaptus Therapeutics (INDP) - Narxning foydaga nisbati|Kapitalizatsiyaning sof foydaga nisbati SCNI (scinai.com)|Narx-foyda koeffitsiyenti CALI|AFMD (Affimed Therapeutics) - Bozor narxining sof foydaga nisbati|P/E multiplikatori ALLK|HOOK - Kapitalizatsiyaning foydaga nisbati|Narxning foydaga nisbati IGM Biosciences IGMS|Kompaniya qiymatining sof foydaga nisbati ITOS|OCEA - Narxning foydaga nisbati|TCBP (TC BioPharm (Holdings) Plc) - Narx-foyda multiplikatori|THRD: P/E multiplikatori
